Variable effects of omaveloxolone (RTA408) on primary fibroblasts with mitochondrial defects.

Zighan, Madleen; Arkadir, David; Douiev, Liza; Keller, Guy; Miller, Chaya; Saada, Ann

Zighan, Madleen; Arkadir, David; Douiev, Liza; Keller, Guy; Miller, Chaya; Saada, Ann.

Afiliación

Zighan M; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Arkadir D; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Douiev L; Department of Neurology, Hadassah Medical Center, Jerusalem, Israel.
Keller G; Department of Genetics, Hadassah Medical Center, Jerusalem, Israel.
Miller C; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Saada A; Department of Genetics, Hadassah Medical Center, Jerusalem, Israel.

Front Mol Biosci ; 9: 890653, 2022.

Article en En | MEDLINE | ID: mdl-36032663

Palabras clave

Omavleoxolone RTA408; Parkinson's disease; ROS; fibroblasts; mitochondria; mitochondrial disease

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Mol Biosci Año: 2022 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google